<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55264">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811732</url>
  </required_header>
  <id_info>
    <org_study_id>RX-3341-302</org_study_id>
    <secondary_id>2012-001767-71</secondary_id>
    <nct_id>NCT01811732</nct_id>
  </id_info>
  <brief_title>Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melinta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melinta Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus
      Aztreonam in the treatment of patients with complicated bacterial and soft tissue
      infections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>area measurements of lesion erythema at primary infection site</measure>
    <time_frame>baseline and at 48 to 72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of systemic and local signs and symptoms of infection</measure>
    <time_frame>up to day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>lesion size, warmth, redness and discharge; White Blood Cell (WBC) count, body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of erythema of ≥30%</measure>
    <time_frame>baseline and at 48 to 72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in pain</measure>
    <time_frame>baseline and at day 5 to 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with methicillin-resistant Staphylococcus aureus  (MRSA) where the pathogen has been eradicated</measure>
    <time_frame>up to day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with pathogen eradication</measure>
    <time_frame>up to day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>Delafloxacin plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg iv every 12 hours for  up to 10 to 28 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin plus Aztreonam + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin 15mg/kg iv plus two grams Aztreonam every 12 hours for up to 10 to 28 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delafloxacin</intervention_name>
    <arm_group_label>Delafloxacin plus placebo</arm_group_label>
    <other_name>RX-3341-83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Vancomycin plus Aztreonam + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aztreonam</intervention_name>
    <arm_group_label>Vancomycin plus Aztreonam + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Delafloxacin plus placebo</arm_group_label>
    <arm_group_label>Vancomycin plus Aztreonam + placebo</arm_group_label>
    <other_name>5% Dextrose</other_name>
    <other_name>D5W</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (≥ 18 years of age) men or women with a diagnosis of Acute Bacterial Skin and
             Skin Structure Infections (ABSSSI) (cellulitis/erysipelas, wound infection, major
             cutaneous abscess, or burn infection) with at least two signs of systemic infection

          -  In the opinion of the investigator, the subject must require and be a suitable
             candidate for IV antibiotic therapy, and the subject must be able and willing to
             comply with protocol requirements

        Exclusion Criteria:

          -  A medical history of significant hypersensitivity or allergic reaction to quinolones,
             beta-lactams, vancomycin, or vancomycin derivatives according to the judgment of the
             investigator

          -  Women who are pregnant or lactating

          -  Any chronic or underlying skin condition at the site of infection that may complicate
             the assessment of response, including infection involving a prosthetic joint, human
             or animal bite, osteomyelitis, decubitus ulcer, diabetic foot ulcer, septic
             arthritis, mediastinitis, necrotizing fasciitis, anaerobic cellulitis, or synergistic
             necrotizing cellulitis, myositis, tendinitis, endocarditis, sustained shock, gangrene
             or gas gangrene; burns covering ≥10% of body surface area; severely impaired arterial
             blood supply to an extremity with an ABSSSI, deep vein thrombosis or superficial
             thrombophlebitis, and requiring either an amputation or multiple debridement
             procedures

          -  Any underlying disease that, in the opinion of the investigator, could interfere with
             the subject's ability to participate in the study including severe cardiac disease,
             known history of liver disease, end-stage renal disease, malignancy, psychiatric
             disorder, ongoing treatment for seizures or untreated history of seizures, or life
             expectancy of &lt;3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Sun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Melinta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugene Sun, MD</last_name>
    <phone>203-848-3342</phone>
    <email>clinicaltrials@rib-x.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Texas</state>
        <zip>77469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10001</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Liepaja</city>
        <zip>LV-3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Valmiera</city>
        <zip>LV-4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Perm</city>
        <zip>614107</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>St. Petersberg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Vsevolozhsk</city>
        <zip>188640</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Chemivtsi</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Klarkiv</city>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Lviv</city>
        <zip>79059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melinta Investigational Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69104</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Croatia</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>March 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial skin infection</keyword>
  <keyword>skin infection</keyword>
  <keyword>infection</keyword>
  <keyword>skin</keyword>
  <keyword>delafloxacin</keyword>
  <keyword>vancomycin</keyword>
  <keyword>aztreonam</keyword>
  <keyword>MRSA bacteria</keyword>
  <keyword>bacterial infection</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
